Miravant Plans Photrex Confirmatory Macular Degeneration Trial
This article was originally published in The Pink Sheet Daily
Executive Summary
The trial, to be conducted under a special protocol assessment with FDA, will be one year with another year for confirmatory results. Agency's September 2004 "approvable" letter for the photodynamic therapy requested an additional study. Miravant is also planning combination studies with other age-related macular degeneration agents.